Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713037 · ClinicalTrials.gov registry record · NA
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
A NA study of Chordoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00713037: Completed NA study of Chordoma, sponsored by Massachusetts General Hospital.
NCT00713037 is a NA study of Chordoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00713037, a NA study of Chordoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is to see if combining the images from the FMISO-PET scan and the CT and MRI scans in radiation treatment planning changes the size and location of the area that will receive radiation treatment when compared to planning the radiation treatment with CT and MRI scans alone.
Conditions Studied
Interventions
- PROCEDURE Fluoromisonidazole-PET/CT
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-06 |
| Est. Completion | 2016-06 |
| Phase | NA |
What the finished NCT00713037 record still lists
NCT00713037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 1 intervention - of which Fluoromisonidazole-PET/CT is the first listed.
NCT00713037 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00713037 about?
NCT00713037 is a clinical study titled "Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas". Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is...
What is the current status of trial NCT00713037?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2016-06.
What conditions does trial NCT00713037 study?
This clinical trial studies the following conditions: Chordoma.
What interventions are being tested in trial NCT00713037?
The interventions under investigation include: Fluoromisonidazole-PET/CT (PROCEDURE).
Who is sponsoring clinical trial NCT00713037?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00713037 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00713037's enrollment target sits among peer trials
20 15th of 15 higher than 1 of 15 other Chordoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chordoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Body Radiotherapy for Spine Tumors
COMPLETED · NA
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
-
Pembrolizumab and Pemetrexed for Progressive Chordoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia